COVID-19: Statement

Tues 24th March 2020: Cancer Trials Ireland issues the following update on the impact of the COVID-19 infection on the clinical operations activity within the Cancer Trials Ireland.

On March 9th Cancer Trials Ireland decided to stop visits to hospital sites. In parallel, most hospitals have also implemented visitor restrictions, both locally in Ireland, and at international hospital sites participating in our trials.

As a result, all planned initiation, monitoring or close-out visits have been cancelled, and no new site visits will be scheduled for the foreseeable future. All studies are affected, including those sponsored by Cancer Trials Ireland (In-house studies) and those sponsored by external sponsors, where monitoring is contracted to Cancer Trials Ireland.

In the meantime and wherever possible, remote monitoring may be implemented as an alternative and in line with our local Competent Authority guidance on the management of clinical trials during COVID-19 (Coronavirus).

As this crisis unfolds, we will keep you updated on any changes to our regulatory guidance, or to Cancer Trials Ireland’s clinical operations decisions.

Please don’t hesitate to contact your Cancer Trials Ireland Project Manager or Clinical Trials Coordinator for study-specific status updates.